Faeth Therapeutics (FTH) Current Leases (2020 - 2026)

Faeth Therapeutics (FTH) has reported Current Leases for 7 consecutive years, with $592000.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Current Leases fell 63.5% year-over-year to $592000.0; the trailing twelve-month figure through Jun 2026 stood at $592000.0 (down 63.5% YoY), and the FY2025 full-year result was $1.4 million, down 13.62% from the prior year.
• Current Leases declined to $592000.0 in Q2 2026 per FTH's latest filing, from $1.0 million in the prior quarter.
• Across five years, Current Leases topped out at $1.7 million in Q3 2025 and bottomed at $592000.0 in Q2 2026.
• Historically, Current Leases has averaged $1.4 million across 5 years, with a median of $1.5 million in 2023.
• The sharpest annual moves came in 2022 and 2026: Current Leases soared 83.97% in 2022, then plunged 63.5% in 2026.
• Over 5 years, Current Leases stood at $1.3 million in 2022, then gained by 25.26% to $1.6 million in 2023, then climbed by 1.21% to $1.6 million in 2024, then declined by 13.62% to $1.4 million in 2025, then slumped by 56.79% to $592000.0 in 2026.
• According to Business Quant data, Current Leases over the past three periods registered $592000.0, $1.0 million, and $1.4 million for Q2 2026, Q1 2026, and Q4 2025 respectively.